6th International Young Scientist Congress (IYSC-2020) will be Postponed to 8th and 9th May 2021 Due to COVID-19. 10th International Science Congress (ISC-2020).  International E-publication: Publish Projects, Dissertation, Theses, Books, Souvenir, Conference Proceeding with ISBN.  International E-Bulletin: Information/News regarding: Academics and Research

To evaluate the effect of Ranolazine on Post Prandial Plasma Glucose in patients of Type-II Diabetes Mellitus with Stable Angina as add on therapy

Author Affiliations

  • 1 Department of Pharmacology, S.H.K.M. Govt. Medical College, Mewat, Haryana, INDIA
  • 2 Department of Gynecology and Obstetrics,S.H.K.M. Govt. Medical College,Mewat, Haryana, INDIA
  • 3 Department of Pharmacology, S.N. Medical College, Agra, INDIA

Int. Res. J. Medical Sci., Volume 2, Issue (1), Pages 7-10, January,28 (2014)

Abstract

The study was aimed to evaluate the effect of Ranolazine on Post Prandial Plasma Glucose(PPPG) in patients of Type –II Diabetes Mellitus with Stable Angina as add on therapy. An open-labeled, randomized, controlled parallel group study was conducted from November 2009 to July 2011 in diagnosed patients of Type –II Diabetes Mellitus with Stable Angina attending the Medicine OPD, Cardiology OPD, Diabetic Clinic and admitted in Medical wards of S.N. medical College and Hospital, Agra. 80 willing patients were recruited on the the basis of inclusion and exclusion criteria. Four patients out of the selected eighty patients refused to take part in study after written consent. The remaining 76 selected patientsrandomly assigned in a1:1 fashion into 2 groups, Control group (Group 1): was on their regular therapy during the 8-week study period. Test group (Group 2): was on Ranolazine 500mg BD (orally) in addition to their regular therapy during the 8-week therapy. The PPPG measurement were done at baseline, repeated after 4 weeks and at the end of treatment(i.e at 8week). Data obtained were presented as mean ± standard deviation (SD). A statistical significance was reported at a two- tailed p value of 0.05. In group I Post Prandial Plasma Glucose (PPPG) concentration was 209.32 ± 15.85 mg/dl at 0 week, 211.11 ± 14.88 at 4 week and 209.01 ± 15.84 at the end of 8 week, whereas for group II, it was 212.37 ± 14.10 at 0 week, 202.61 ± 10.84 at 4 week and 202.47 ± 10.72 at the end of 8 week. There was decrease in PPPG in Group II and this decrease was statistically significant with P value 0.05 in comparison to group I at end of 8 week after treatment. Ranolazine significantly reduced PPPG in patients of Type –II Diabetes Mellitus with Stable Angina as add on therapy in addition to their regular therapy. As this is a smaller study, larger studies are needed to show the definite effect of Ranolazine on PPPG.

References

  1. Grundy S.M., Benjamin I.J., Burke G.L., Chait A., Eckel R.H., Howard B.V., Mitch W. and Smith S.C. Jr, Sowers JR., Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association, Circulation., 100, 1134–1146 (1999)
  2. American Heart Association. Heart Disease and Stroke Statistics: 2006 Update, Dallas, Tex: American Heart Association, (2006)
  3. Mozaffarian D., Marfisi R., Levantesi G., Silletta M.G., Tavazzi L., Tognoni G., Valagussa F. and Marchioli R., Incidence of new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factors, Lancet., 370, 667–675 (2007)
  4. Donahoe S.M., Stewart G.C., McCabe C.H., Mohanavelu S., Murphy S.A., Cannon C.P. and Antman E.M., Diabetes and mortality following acute coronary syndromes, JAMA., 298, 765–775 (2007)
  5. Hanefeld M., Fischer S., Julius U., Schyulze J., Schwanebeck U., Schmechel H., Ziegelasch H.J. and Lindner J., (The DIS Group), Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up, Diabetologia., 39, 1577–1583 (1996)
  6. Pepine C.J. and Cooper-Dehoff R.M., Cardiovascular therapies and risk for development of diabetes, J Am Coll Cardiol., 44, 509–512 (2004)
  7. Chaitman B.R., Pepine C.J., Parker J.O., Skopal J., Chumakova G., Kuch J., Wang W., Skettino S.L. and Wolff AA., Effects of Ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial, JAMA., 291, 309–316 (2004)
  8. Chaitman B.R., Skettino S.L., Parker J.O., Hanley P., Meluzin J., Kuch J., Pepine C.J., Wang W., Nelson J.J., Hebert D.A. and Wolff A.A., Anti-ischemic effects and long-term survival during Ranolazine monotherapy in patients with chronic severe angina, J Am Coll Cardiol., 43, 1375–1382 (2004)
  9. Timmis A.D., Chaitman B.R., Crager M., Effects of Ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes, Eur Heart J., 27, 42–48 (2006)
  10. Chisholm J.W., Goldfine A.B., Dhalla A.K., Braunwald E., Morrow D.A., Karwatowska-Prokopczuk E. and Belardinelli L., Effect of Ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome, Diabetes Care., 33, 1163–1168 (2010)
  11. Trinder P., Glucose assay: A colorimetric enzyme- kinetic method assay, Ann. Clin Biochem., 6, 24 (1969)
  12. Donahue R.P., Abbott R.D., Reed D.M. and Yano K., Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry (Honolulu Heart Program), Diabetes., 36, 689–692 (1987)
  13. DECODE Study Group., Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria, Lancet., 354, 617–621 (1999)
  14. De Vegt F., Dekker J.M., Ruhe H.G., Stehouwer C.D., Nijpels G., Bouter L.M. and Heine R.J., Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study, Diabetologia., 42, 926–931 (1999)
  15. Hanefeld M., Koehler C., Schaper F., Fuecker K., Henkel E. and Temelkova-Kurktschiev T., Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals, Atherosclerosis., 144, 229–235 (1999)
  16. Dhalla A.K., Liu D., Santikul M. and, Belardinelli L., Ranolazine increases glucose stimulated insulin secretion in rats, J Am Coll Cardiol.,51, A321 (2008)